Dr Xiuping Chen has been a full professor at the University of Macau since 2021. He has over 20 years' experience in pharmacological research, particularly focusing on screening and identifying regulators of programmed cell death (PCD) and epithelial-mesenchymal transition (EMT) from natural compounds. His work aims to discover lead compounds or potential therapeutics for cancers, cardiovascular diseases and fibrotic disorders. His notable accolades include the 17th SERVIER Young Pharmacologist Award in 2013 and Second Prize in the Macao Science and Technology Awards in 2012 and 2014. He is a Member of the Royal Society of Biology and has been chairman of the Macau Society of Pharmacology and Toxicology since 2024. He is the senior editor of the British Journal of Pharmacology and has authored over 100 publications, which have received more than 17,000 citations. His current h-index is 70.

Dr. Shouvik Choudhury is an Assistant Professor of Pharmacology at Burdwan Medical College, West Bengal, India. He earned his MBBS from Burdwan Medical College (2011) and an MD in Pharmacology from the Institute of Post Graduate Medical Education and Research, Kolkata (2018). Dr. Choudhury has over a decade of experience in teaching, research, and clinical pharmacology, having served as Senior Resident and Demonstrator prior to his current role. He has authored two widely used books on pharmacology and biostatistics, and published more than 40 articles in national and international indexed journals. His research has been presented at global forums, including the World Congress of Pharmacology in 2018 and 2023. Dr. Choudhury also serves as Deputy Coordinator of the Pharmacovigilance Committee at Burdwan Medical College, contributing to advancements in safe and effective medication use.

Nuala Helsby FBPhS is a New Zealand academic, and is a professor of molecular medicine and pathology at the University of Auckland. She has more than 30 years of experience in drug metabolism and pharmacogenetics with a particular focus on the safe and effective use of currently used anticancer drugs.

Prof. Cimi Ilmiawati, MD, PhD is a faculty member of the Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, Indonesia, where she has served since 2008. She currently holds the position of Head of the Master’s Program in Biomedical Sciences at the same faculty. She obtained her medical degree from Universitas Andalas in 2006 and completed her Ph.D. in Environmental Health and Preventive Medicine at Jichi Medical University, Japan, in 2014. Dr. Ilmiawati has undertaken postdoctoral research in Japan supported by the Takeda Science Foundation (2016) and in the United States as a Fulbright Visiting Scholar (2021). Dr. Ilmiawati teaches at undergraduate, master’s, and doctoral levels in medicine, biomedical sciences, and public health. Her expertise lies in environmental toxicology, with molecular biology and epidemiological approaches. Her research has been published in reputable international and national journals and presented at numerous scientific conferences. Currently, her work focuses on potentially toxic compounds in cosmetics and their health impacts on women of reproductive age.

Dr. Koki Abe is an Assistant Professor in the Department of Pharmacology at Sapporo Medical University, Japan. His research investigates the molecular mechanisms of anticancer drug-induced nephropathy, focusing on programmed cell death pathways. He aims to develop preventative strategies for anticancer drug-induced nephropathy.

Prof. Byung-Hoon Lee is a professor at the College of Pharmacy at Seoul National University (SNU), specializing in toxicology, cancer, autophagy, and chaperone-mediated autophagy. He earned his B.S. and M.S. from SNU and holds a Ph.D. from Heidelberg University. His research focus includes protein degradation mechanisms and SNX10-mediated degradation of LAMP2A by NSAIDs.

Dr Jayanthi Mathaiyan is currently affiliated to JIPMER, Puducherry, India, an institute of National Importance funded by Ministry of Health & Family Welfare, India. She has a teaching and research experience of 18 years having guided several MD Pharmacology, PhD and MBBS students in research in the fields of Rational Use of Medicines, Pharmacogenomics and Pharmacovigilance. She has about 65 peer reviewed publications to her credit and has received both institutional and extramural funds for her researach work. She was the Head of Departement of Pharmacology, JIPMER from 2020 - 2022 (3 years), Member Secretary of Insitutional Ethics Committee for Interventional studies from 2018 - 2021 and a member of several research committees at JIPMER. She has been a resource person for workshops on Bioethics, Pharmacogenomics, Research Methodology and Biostatistics across the country.

I am a rehabilitation physician from Sydney, with an interest in regulatory medicine, chronic pain and Aboriginal Health. I have worked as a consultant in metropolitan, rural and regional centres in New South Wales and Tasmania. I contribute to Aboriginal Medical Services in Wollongong, Armidale and Kempsey in NSW. Outside of medicine, for me there's faith, family and community.

Dr Natalie Anderson is the Regulatory Science Officer at Animal-Free Science Advocacy (AFSA) and a leading national advocate for humane, animal-free research and science in Australia. With a PhD in Public Health and a background in paediatric medical research, she works to advance modern, non-animal technologies that protect both human health and animal lives. Natalie regularly speaks at state and national conferences, sharing the growing evidence that modern, non-animal technologies are not only more ethical, but often more effective for human health. She contributes her expertise to regulatory bodies, research panels, and industry groups, helping to shift scientific practice away from animal experimentation both nationally and internationally.

Dr. Gestina Aliska, Sp.FK, is a lecturer in the Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, and a Clinical Pharmacologist at Dr. M. Djamil General Hospital, Padang, West Sumatra, Indonesia. She obtained her medical degree from Universitas Andalas and completed her Clinical Pharmacology specialist training and doctoral degree in Medical Sciences at Universitas Indonesia. Her research focuses on clinical pharmacology, with particular interests in sepsis, COVID-19, antimicrobial resistance, and pharmacogenomics. Her work emphasizes pharmacokinetic/pharmacodynamic optimization, therapeutic drug monitoring, biomarker-based therapy, and individualized treatment strategies in critically ill patients. Dr. Aliska is actively involved in funded clinical research, international scientific publications, and undergraduate and postgraduate medical education. She teaches clinical and molecular pharmacology and contributes to the development of evidence-based pharmacotherapeutic practices, with a strong commitment to advancing rational and personalized medicine in Indonesia.

I am a dual trainee in Clinical Genetics and Clinical Pharmacology through the paediatric training pathway, with a strong interest in translational genomics, gene therapies, and precision medicine. Alongside my clinical training, I work in the Monash Children's Hospital clinical trials unit. I hold a PhD in genetic research focused on inherited disorders and have a strong interest in integrating genomic technologies into clinical care, particularly for rare genetic diseases. My work centres on advancing precision genomic medicine through clinical research and emerging therapeutic platforms, including RNA-based and gene-editing therapies.

She has been undertaking postdoctoral training at the First Clinical Medicine Postdoctoral Research Station of Jinan University. Her research focuses on elucidating the roles and underlying mechanisms of lipid metabolism in aging-related disorders affecting bone, muscle, and skin, as well as in neural injury. Based on well-defined molecular targets, her current work also involves the discovery and pharmacological evaluation of bioactive compounds, including traditional Chinese medicines, natural products, and small bioactive peptides. To date, she has published multiple peer-reviewed articles as first or co-first author in journals including Nature Communications, Cell Investigation, Food & Function, and The FASEB Journal. She currently holds 10 authorized Chinese patents, with 2 patents successfully commercialized.

Dr. Khushboo Bisht, MD, DM (Clinical Pharmacology), is an Assistant Professor at AIIMS Nagpur. She specializes in translational research and clinical pharmacology, with particular expertise in pharmacokinetics and pharmacometrics. Over the past decade, she has authored 15 publications indexed in PubMed and holds an H-index of 4. Dr. Bisht is also an Associate Fellow of the National Academy of Medical Sciences.

Hua-Ching Chang is a Dermatologist at Taipei Medical University Hospital and serves as an Assistant Professor at Taipei Medical University. He is also pursuing his Ph.D. in the Graduate Institute of Pharmacology at National Taiwan University. His research primarily focuses on evidence-based medicine, particularly through systematic reviews and meta-analyses, as well as the fields of immunology and pharmacology in dermatology.

Dr. Kumud Chapagain is an Associate Professor of Clinical Pharmacology with extensive experience in teaching, research, and mentorship. She earned her MD from Tribhuvan University, Nepal (Gold Medalist), and MBBS from the University of Science and Technology Chittagong, Bangladesh (First Position). She has completed specialized research training through the Global Clinical Scholars Research Training (GCSRT) at Harvard Medical School, the Principles and Practice of Clinical Research (PPCR) at Harvard Medical School and Harvard T. H. Chan School of Public Health, and the FAIMER Fellowship program, and currently serves as a Teaching Assistant in the PPCR program. Her research focuses on pharmacoepidemiology, medication adherence, quality use of medicines, real-world medication use, and medicine safety. She is an Early Career Editorial Board Member of Biomedicines (MDPI).

Prof. Rakesh Kumar Dixit is working as Professor and Head of Pharmacology and Therapeutics at King George's Medical University, Lucknow, India. I completed an MD in Pharmacology in 1997 and worked as a senior resident at the Postgraduate Institute of Medical Education and Research, Chandigarh. After that, I joined King George's Medical University, Lucknow, Uttar Pradesh, India in 2002 as an assistant professor. I became a Professor in 2010 and Head of the department in 2024. My passion is teaching. I am a faculty member in the medical education unit and coordinator of the Master's in Health Professional Education. I have published 129 research papers and authored 7 books. I have been president of the National Association of Pharmacology and Therapeutics and founder of the Association of Community Pharmacotherapeutics. It will be great learning to attend the WCCP 2026.

Ioan Magyar is an Assoc. Professor of Basic & Clinical Pharmacology since 2004 at University of Oradea, Romania. He is also involved in clinical activity in Emergency Department of Pediatrics. He attain an additional competence in Clinical Toxicology.

Shen Wandong (born September 1971), female, Han ethnicity, native of Fuling District, Chongqing, currently serves as Deputy Chief Nurse in the Pediatrics Department of Fuling District Maternal and Child Health Hospital, Chongqing. She graduated from Chongqing Medical University with a Bachelor's degree in Clinical Medicine, specializing in Internal Pediatrics. With solid theoretical knowledge and extensive clinical experience, she has earned high praise from colleagues and patients during her professional practice.

Liganda Endo Mahata is a candidate clinical pharmacology specialist with a strong interest in drug safety, pharmacovigilance, and real-world data analysis. Her work focuses on translating complex pharmacological evidence into clinically meaningful insights, particularly in the areas of adverse drug reactions, drug–drug interactions, and benefit–risk assessment. With a background in medicine, biomedicine, and clinical pharmacology, she is actively involved in clinical research and academic activities. This includes the analysis of large pharmacovigilance databases and the application of disproportionality methods to support post-marketing drug safety evaluation. Her research interests also extend to cardiovascular pharmacology and immunotherapy-related adverse events, with an emphasis on evidence-based practice and rational drug use.

Hong Jun-ki is a Ph.D. candidate in Clinical Pharmacology at Seoul National University College of Medicine. His research focuses on drug development and pharmacological evaluation, including biomarker functional studies, in vitro and in vivo drug efficacy assessment, and non-clinical trial-based modeling. He applies these findings to clinical trial simulation and Phase I clinical trial design, bridging preclinical evidence with early-phase human studies. He is also engaged in pharmacovigilance, contributing to post-market drug safety monitoring. Through an integrative approach combining experimental and computational methodologies, he aims to advance the translation of novel therapeutics from bench to bedside.

Dr Ali Hosin is a Specialty Registrar in Clinical Pharmacology & Therapeutics and Internal Medicine, and a DPhil candidate at the University of Oxford. His research evaluates novel digital technologies in cardiovascular disease, assessing impacts on safety, healthcare utilisation and patient outcomes. Ali graduated from Imperial College School of Medicine, completed Academic Foundation Training at Guy’s and St Thomas’ Hospitals, and held an NIHR Academic Clinical Fellowship in Clinical Pharmacology & Therapeutics at University College London. Ali's interest in digital health research developed with the rapid expansion of remote care during the COVID-19 pandemic. He led the implementation and evaluation of app-enabled remote blood pressure (BP) monitoring for hypertension and, as Chief Registrar, implemented this for high-risk acute stroke patients at the National Hospital for Neurology & Neurosurgery. Ali is a keen medical educator and teaches prescribing, therapeutics and medication safety at UCL and Oxford.

Iribhogbe Osede Ignis was born in Kwale, Delta State, Nigeria, into a Christian family. He completed his primary and secondary education in Lagos State, Nigeria, which provided him with a multicultural exposure that prepared him for higher education. In 2005, he earned his MBBS degree from the University of Jos and completed his internship at Irrua Specialist Teaching Hospital, Irrua, Edo State, between December 2005 and December 2006. His interest in Basic and Clinical Pharmacology led him to pursue postgraduate training at the University of Lagos, Nigeria, where he obtained a Master of Science in 2008 and a Ph.D. in Pharmacology in 2014. Dr. Ignis’s research focuses on pharmacoepidemiology and drug utilization, as well as clinical and experimental therapeutics and nutriceuticals. Over the years, he has valued the cross-fertilization of ideas with innovative individuals, believing that such interactions foster new ideas based on recent information and experiences. To maximize the benefits of this approach, he conducts extensive research on new theories and concepts generated through collaborative and cohesive interactions. He has published several articles in both local and international journals, with his work profiled in academic repositories including Google Scholar and Loop Frontiers in Pharmacology. In addition, Dr. Ignis has held multiple administrative positions in professional associations, Christian organizations, and at the College of Medicine, Ambrose Alli University, Ekpoma.

Mitchel Hurlbert is a clinician at St Vincent’s Hospital with a strong interest in clinical pharmacology, rheumatology, biologic therapies, and health-system stewardship. His work focuses on the evaluation of high-cost medicines, including real-world utilisation of rituximab across speciality services. He has previously conducted analyses on PBS data on rituximab from 2015-2025. Looking at dispensing changes and cost at state and federal levels. His academic interests lie at the intersection of clinical pharmacology, pharmacogenomics, and systemic inflammatory diseases. In the future he aims to dual train Clinical pharmacology with Rheumatology, bringing foundational principals of clinical pharmacology to inflammatory conditions with cutting edge individualized treatments.

Graduated from Chongqing Medical University with a master's degree, currently serving as an attending physician and nationally registered nutritionist. Completed advanced training in chronic disease nutrition management at the Clinical Nutrition Department of West China Hospital, Sichuan University, and studied intestinal microecological nutrition technology at the Clinical Nutrition Department of the Second Affiliated Hospital of Guangzhou Medical University.

Dr Blessing Airhihen is a Pharmacist with a PhD in Biomolecular Science from the School of Pharmacy, University of Nottingham. Since 2005, her teaching and research career has been predominantly focused on early-phase drug discovery in oncology, target validation, and protein therapeutics. She transitioned from AstraZeneca PLC to Nottingham Trent University (NTU) as a Senior Lecturer. She is a Senior Fellow of the Higher Education Academy (SFHEA), passionate about enhancing the student experience. Dr Airhihen employs innovative pedagogy and co-creation in her teaching design and practice at NTU and beyond. She founded STEMspiration, a platform that inspires international women in STEMM and early-career professionals. She continues to develop and extend her scholarship practice and mentoring initiatives, empowering women, undergraduates, and postgraduates both at NTU and beyond the UK.

Dr. Mirunalini R is an Associate Professor of Pharmacology at JIPMER, a postgraduate teaching hospital and institute in Puducherry, South India. She has nearly 10 years of experience in teaching and research and has guided undergraduate and postgraduate medical students (MD/MS and DM) in dissertation and short-term research projects. Her research focuses on drug resistance, pharmacovigilance, and estimating the burden of drug resistance and its impact on disease progression in tuberculosis patients. She is involved in collaborative research projects in tuberculosis, pharmacovigilance, and drug resistance. Dr. Mirunalini is the Principal Investigator at the JIPMER site for a DBT Ramalingasamy Fellowship project on nanopore sequencing-based pharmacogenomics and pharmacokinetics of first-line anti-tuberculosis drugs. She is also a Co-Investigator on ICMR-sponsored studies under ICMR-INTENT and the Centre for Advanced Research program. She has received awards for best thesis and best presentation (JK Dutta and UK Seth).

Igor Rubinić, MD, is a clinical pharmacologist at the Clinical Hospital Centre Rijeka and a doctoral student in biomedical sciences at the Faculty of Medicine, University of Rijeka, Croatia. His research focuses on antimicrobial stewardship, multidrug-resistant organisms, and microbiome-based interventions, including faecal microbiota transplantation. He is a member of EurFMT and serves on the Executive Board of the European Drug Utilization Research Group (EuroDURG).

Sivakova Olga Dmitrievna was born on April 12, 1983. She graduated from Samara State Medical University with a degree in general medicine in 2006. During her studies at the university, she showed interest in scientific work; consisted in a student circle, participated in student scientific conferences. At the end of the university, from 2006 to 2007, studied at a clinical internship in the specialty "therapy" at the Department of Faculty Therapy of the Samara State Medical University. During her internship, she improved her patient management skills, mastered modern methods of diagnosis and treatment in accordance with the program. After completing her internship in 2007, she completed a specialization in clinical pharmacology and worked as a clinical pharmacologist at the Department of Clinical Pharmacology of a large regional hospital. In 2011, she entered full-time postgraduate study at the Samara State Medical University with a degree in pulmonology, continuing to combine active practical activities with postgraduate studies. Sivakova O.D. has established herself as an attentive, disciplined and competent specialist. She has a high level of theoretical and practical training, which is constantly improving. Disciplined, hardworking, responsible. Actively participates in the medical and organizational practical work of the Clinics. In her work, she uses the full range of modern methods of diagnosing and treating patients, guided by the principles of evidence-based medicine. Sivakova O.D. successfully engaged in scientific work in the field of practical pulmonology. In 2014, she defended her thesis on the clinical, pharmacoepidemiological features of community-acquired pneumonia in the Samara region. The results of the study are used in the work of the Samara Regional Center for Occupational Pathology, Department of Allergology and Pulmonology Clinics. She has 17 publications on various topics, has repeatedly made research results at conferences of various levels. At the moment, Olga Sivakova is the head of the department of clinical pharmacology of a large multidisciplinary hospital, conducts daily consultations of severe comorbid patients, is engaged in organizational and scientific activities. Married, has two children. In her free time, she enjoys cooking and traveling.

Dr. Umberto Villani earned his MSc in Bioengineering from the University of Padova, Italy, in 2018. He then worked on the biophysical modelling of magnetic resonance imaging techniques, obtaining a PhD in biomedical imaging applied to Neuroscience in 2022. Until 2024, he was a Postdoctoral Fellow in Translational Pharmacology at the National Research Council in Rome, where he contributed to the development of quantitative methods to evaluate the efficacy of novel drugs and drug combinations against tuberculosis. He is currently a Postdoctoral Researcher in Clinical Pharmacology at UCL’s School of Pharmacy, within the Clinical Pharmacology and Therapeutics Group, where his work centres on applying Modelling & Simulation techniques to accelerate the approval of new medicines for paediatric rare diseases.

Dr. João Paulo Ximenez is an Assistant Professor at the University of São Paulo (Brazil). His research focuses on understanding interindividual variability in drug response, particularly in infectious diseases such as HIV, tuberculosis, and neurocryptococcosis. He integrates clinical pharmacokinetics, pharmacogenetics, and data-driven approaches, including machine learning, to develop models for predicting drug exposure and optimizing dosing strategies. His work emphasizes the use of limited sampling strategies, endogenous biomarkers, and multi-omics data to support precision dosing and personalized therapy. Dr. Ximenez has authored multiple peer-reviewed publications in clinical pharmacology and collaborates with national and international research groups. He is also actively involved in training undergraduate and graduate students and in developing translational research projects bridging experimental and clinical pharmacology.

Nonoka Aoki is a pharmacy student in the School of Pharmaceutical Sciences at the University of Shizuoka, Japan, where she conducts her undergraduate research in the Laboratory of Pharmacy Practice and Sciences. Her research focuses on developing patient-friendly oral dosage forms to improve medication adherence. She explores formulation design of medicines to improve the palatability, usability, and overall acceptability. She is particularly interested in creating oral formulations and health products that patients can take more comfortably and enjoyably, with an emphasis on better taste and texture. She hopes to contribute to providing safer and more pleasant medication experiences for patients. She will obtain her pharmacist license and hopes to pursue work in the development of palatable oral medicines and health products after graduation.

Fatimata Seydy Ball is a pharmacist. She holds a Master's degree in Drug Development, specializing in Pharmacology. Fatimata Seydy Ball is in the final stages of her PhD thesis in pharmacology.

My name is Dr. Ahsan Aslam. I am working as a assistant professor of Pharmacology at Indus Medical College, Pakistan.

Dr. Shouvik Choudhury is an Assistant Professor of Pharmacology at Burdwan Medical College, West Bengal, India. He earned his MBBS from Burdwan Medical College (2011) and an MD in Pharmacology from the Institute of Post Graduate Medical Education and Research, Kolkata (2018). Dr. Choudhury has over a decade of experience in teaching, research, and clinical pharmacology, having served as Senior Resident and Demonstrator prior to his current role. He has authored two widely used books on pharmacology and biostatistics, and published more than 40 articles in national and international indexed journals. His research has been presented at global forums, including the World Congress of Pharmacology in 2018 and 2023. Dr. Choudhury also serves as Deputy Coordinator of the Pharmacovigilance Committee at Burdwan Medical College, contributing to advancements in safe and effective medication use.

Prof. Rakesh Kumar Dixit is working as Professor and Head of Pharmacology and Therapeutics at King George's Medical University, Lucknow, India. I completed an MD in Pharmacology in 1997 and worked as a senior resident at the Postgraduate Institute of Medical Education and Research, Chandigarh. After that, I joined King George's Medical University, Lucknow, Uttar Pradesh, India in 2002 as an assistant professor. I became a Professor in 2010 and Head of the department in 2024. My passion is teaching. I am a faculty member in the medical education unit and coordinator of the Master's in Health Professional Education. I have published 129 research papers and authored 7 books. I have been president of the National Association of Pharmacology and Therapeutics and founder of the Association of Community Pharmacotherapeutics. It will be great learning to attend the WCCP 2026.

Prof. Rakesh Kumar Dixit is working as Professor and Head of Pharmacology and Therapeutics at King George's Medical University, Lucknow, India. I completed an MD in Pharmacology in 1997 and worked as a senior resident at the Postgraduate Institute of Medical Education and Research, Chandigarh. After that, I joined King George's Medical University, Lucknow, Uttar Pradesh, India in 2002 as an assistant professor. I became a Professor in 2010 and Head of the department in 2024. My passion is teaching. I am a faculty member in the medical education unit and coordinator of the Master's in Health Professional Education. I have published 129 research papers and authored 7 books. I have been president of the National Association of Pharmacology and Therapeutics and founder of the Association of Community Pharmacotherapeutics. It will be great learning to attend the WCCP 2026.

Prof. Rakesh Kumar Dixit is working as Professor and Head of Pharmacology and Therapeutics at King George's Medical University, Lucknow, India. I completed an MD in Pharmacology in 1997 and worked as a senior resident at the Postgraduate Institute of Medical Education and Research, Chandigarh. After that, I joined King George's Medical University, Lucknow, Uttar Pradesh, India in 2002 as an assistant professor. I became a Professor in 2010 and Head of the department in 2024. My passion is teaching. I am a faculty member in the medical education unit and coordinator of the Master's in Health Professional Education. I have published 129 research papers and authored 7 books. I have been president of the National Association of Pharmacology and Therapeutics and founder of the Association of Community Pharmacotherapeutics. It will be great learning to attend the WCCP 2026.

Annie Ea is a PhD Candidate from the Centre for Medicine Use and Safety at Monash University. Her research investigates the role of knowledge brokers to implement clinical practice guidelines for safe and effective medication management. She is particularly interested in improving guideline implementation in residential aged care. Annie obtained her Bachelor of Pharmacy (Honours) and Master of Pharmacy at Monash University. Alongside her PhD, Annie serves as Lead Pharmacist at St John Ambulance Victoria and continues to practice as a clinical pharmacist in general and geriatric medicine.

El Hadji Dione is a pharmacist and former hospital intern. He holds a Master's degree in Drug Development, specializing in Pharmacology. El Hadji Dione is in the third year of a PhD thesis in Pharmacology. He also holds a postgraduate diploma in Clinical Biology.

Priyadharshani Galappatthy, MBBS(Col), MD(Col), MRCP(UK), DipMedTox(Cardiff), FCCP, FRCP(Lond) is Senior Professor and Chair Professor of Pharmacology, Faculty of Medicine University of Colombo, Sri Lanka. She was a WHO Consultant, in the Patient Safety and Quality of Care Unit, WHO Headquarters Geneva, Switzerland from 2022-2024. She was involved in the planning of the WHO third Global Patient Safety Challenge on Medication Without Harm, launched in 2017. She provided technical support for drafting the National Action Plans on medication safety 2021-2025 and the updated draft 2026-2030 and support the implementation. She is the immediate past president of Sri Lanka Association of Clinical Pharmacology and Therapeutics. She currently supports the Joint Commission International on improving patient safety through their ‘Patient Safety Pathways’ initiative launched in 2025. As a member of the Board of Directors of the National Medicines Regulatory Authority, she contributes to medicines regulation in Sri Lanka.

Anping Guo is currently serving as the Deputy Director of the Department of Pharmacy of the First Affiliated Hospital of USTC. With extensive experience in pharmaceutical management and health economics, Anping Guo has demonstrated exceptional research capabilities and leadership. Her works have greatly advanced the development of hospital pharmacy management and health economics research. Additionally, Anping Guo has made significant contributions to the study of diabetes and its complications, particularly in exploring the pathogenesis of these conditions and identifying potential drug treatment targets.

Dr. Shazia Hasan is an Associate Professor in the Department of Pharmacology at AIIMS Rishikesh, India. She is actively involved in undergraduate (MBBS) and postgraduate (MD and MSc Pharmacology) medical education, academic mentoring, and research. Her key areas of interest include ecopharmacology, pharmacovigilance, patient safety, rational therapeutics, and healthcare sustainability. She has contributed to scientific publications, delivered academic presentations, and participated in initiatives aimed at strengthening safe and evidence-based medicine practices. Dr. Hasan is dedicated to advancing academic excellence in pharmacology and promoting responsible and environmentally conscious healthcare practices.

Dymphy Huntjens brings over 20 years of international experience in the pharmaceutical industry, specializing in pre-clinical and clinical quantitative drug development. She holds a PhD in Pharmacometrics from Leiden University in the Netherlands, where she also studied Bio-Pharmaceutical Sciences. Dymphy began her career as a clinical pharmacometrician at Grünenthal in Aachen, Germany. Before joining Priothera, she served as Scientific Director at Johnson & Johnson. As a global clinical pharmacology and pharmacometrics lead, Dymphy has overseen projects spanning both early and late stages of development. She has designed, executed, and analyzed innovative clinical development plans and studies. Her expertise spans a range of therapeutic areas, including infectious diseases, neurosciences, and oncology. Throughout her career, Dymphy has played a pivotal role in advancing drugs from the pre-clinical stage to first-in-human trials, through proof of concept, and ultimately to successful regulatory filings.

Dr. Rajesh Kumawat is head of Medical Services & Clinical Development at Himalaya Wellness Company, Bengaluru, India. He is a qualified medical expert with over 30 years of total experience in the academia, public health & pharmaceutical industry, with key roles at reputed MNCs like Lupin, Fresenius Oncology, and Ranbaxy (Sun Pharma). He completed MBBS from J.L.N. Medical College, Ajmer, India & MD (Pharmacology) at SMS Medical College, Jaipur (India). As a public health administrator, he was involved in organizing, supervising, reviewing and implementation of various national health programs in communicable diseases for Government of Rajasthan, India. He also Spearheaded the pilot project of RNTCP (Tuberculosis program in India) as MOTC (Medical Officer Tuberculosis control) under umbrella of WHO (World Health Organization). His industry expertise includes various domains such as Clinical Development, Scientific Strategy, Medical Writing and Clinical Operations. He spearheaded many Phase I - IV, clinical development & multicentric clinical trials in multiple therapeutic domains for DCGI, USFDA, MHRA submissions. Privileged to be one among the expertise to have exposure of strategy & execution of Global Phase 1 study. Currently, he oversees medical and clinical development for Himalaya's products globally and implementation of Pharmacovigilance in herbal industry. He has many publications in his name at various prestigious journals & also has participated as guest speaker at various national & International platforms.

Dr Shrutika Kumawat 3rd year PG resident MD Pharmacology in Government Medical College Gondia, Maharashtra, India, MUHS university. Completed MBBS. Presenting and Participating in the International Conference first time.

Dr. Ved Prakash is an Assistant Professor in the Department of Pharmacology at the Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, India. He is also coordinator of Pharmacovigilance program of India at IMS-BHU, India. He holds an MBBS and MD in Pharmacology from Government Medical College, Patiala, India and has over a decade of experience in medical teaching, clinical research, and pharmacological sciences. He is actively involved in undergraduate, postgraduate and PhD teaching in pharmacology, with a focus on strengthening conceptual understanding and clinical application of pharmacological principles. Dr.Prakash’s areas of expertise include clinical pharmacology, pharmacovigilance, and metabolic disorders, with a strong emphasis on evidence-based medicine and rational drug use. He has contributed significantly to medical education through formal training programs, including medical education training at KGMU and Good Clinical Practice (GCP) certification from IMS-BHU. He has an extensive background in clinical and experimental research, with several PubMed-indexed publications in the past year. His research work spans metabolic disorders, diabetes mellitus, dyslipidemia, antifungal therapies, adverse drug reaction monitoring, and drug safety. He has authored multiple papers as first and corresponding author in peer-reviewed national and international journals. Dr. Prakash has served as Principal Investigator for several funded and unfunded research projects, including IoE-BHU–funded studies on green tea extract (Camellia sinensis) in experimental diabetes and the anti-inflammatory and anabolic effects of Withania somnifera in collagen-induced arthritis. He has also led clinical studies on lipid-lowering therapies, antiretroviral treatment outcomes, and active pharmacovigilance initiatives in North Indian populations. In recognition of his scholarly contributions, he has received several professional trainings and honors, including an observership at AIIMS New Delhi, participation in a WHO workshop on research methodology, and the First Prize for scientific presentation at NAPTICON 2023 Lucknow, India. Dr.Prakash remains actively engaged in teaching, research, and pharmacovigilance activities, with a commitment to advancing clinical pharmacology, strengthening drug safety systems, and improving patient-centered therapeutic outcomes.

Dr Emily Reeve is a Senior Research Fellow and NHMRC Emerging Leadership Fellow. She is Deputy Theme Lead of the Centre for Medicine Use and Safety at Monash University and Chair of the Australian Deprescribing Network (ADeN). Dr Reeve worked as a clinical pharmacist at the Royal Adelaide Hospital before completing a PhD at the University of South Australia.

Dr Sato is a research fellow, and working at Departments of Clinical Pharmacology and Aged Care, Faculty of Medicine and Health, The University of Sydney, Kolling Institute, Royal North Shore Hospital. Before starting her current position, she completed a Master of Public Health and a PhD in Pharmacy at the University of Sydney, focusing on the quality use of medicines in geriatric primary health care. She has a unique skill set, combining expertise in big data analysis, epidemiology, pharmacology, clinical experience in both hospital and community pharmacy settings. Additionally, she has advanced IT skills, including programming (Python, R, JavaScript) and software (SAS, REDCap, Qualtrics).

I am an early-career researcher with academic training in chemistry and clinical research and a strong interest in public health. I hold a Bachelor’s degree in Chemistry (Honours) and a Master’s degree in Clinical Research from the Translational Health Science and Technology Institute (THSTI), Faridabad. I completed my master’s thesis at the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi, in the Department of Gastroenterology. During my postgraduate training, I published an article titled “Medication Adherence in Clinical Trials” in the International Journal of Pharmacy Practice. I have a strong interest in research and am motivated to continue working in the fields of clinical research and public health. My research interests include evidence-based medicine, clinical trials, and improving healthcare outcomes through high-quality research.

Wang Jiaxing, a doctoral student at Harbin Medical University. Research support units: National Key Laboratory of Cold Region Cardiovascular Diseases at Harbin Medical University, Key Laboratory of Intestinal Microbiota and Pharmacogenomics in Heilongjiang Province, National Provincial Key Laboratory of Biomedicine in China, and the Center for Infection and Genomics of the Karagali University College of Medicine at the University of Calgary. The research field of this project focuses on the treatment of ovarian cancer, and the research direction is dedicated to the intestinal microbiota metabolites of natural plant lignans - intestinal esters. It explores the pharmacological activity and target points of these substances in the treatment of ovarian cancer, and investigates their efficacy evaluation in the process of fighting ovarian cancer and the exploration of potential pharmacological mechanisms.

A/Prof. Dr. Abraham Simatupang is Head of the Department of Pharmacology & Therapy at Universitas Kristen Indonesia (UKI) and Founder of several educational and community health initiatives. He holds a Doctorate in Medicine from the University of Bonn, Germany, an MSc from Universitas Gadjah Mada, and an MD from UKI. Dr. Simatupang has over two decades of experience in pharmacology, medical education, and public health. He has led research projects on HIV/AIDS, medical cannabis, herbal medicine, and adverse events following COVID-19 vaccination. He has published extensively and is a reviewer for multiple national and international journals. He has developed innovative educational programs, including HIV/AIDS modules and Integrative Pharmacotherapy clerkships, and co-founded the Bakung HIV/AIDS Clinic and the Lentera Anak Pelangi Foundation supporting children with HIV/AIDS. Dr. Simatupang has received multiple fellowships and certifications, including DAAD scholarships and advanced training in medical cannabis. He is a member of the Indonesian Pharmacology Association, British Pharmacology Society, ASCEPT, and a past President of the German-Indonesian Medical Association (DIGM).

Prof Janet Sluggett is a Professor of Pharmacy and Pharmacoepidemiology at Adelaide University. Janet is a pharmacist and her research seeks to improve medicines use, safety and effectiveness in older people accessing aged care services. Janet's work also focuses on the delivery and outcomes of pharmacist services in aged care settings.

Dr Michelle Tan is a Research Fellow (National Dementia Clinical Guidelines Development) at the Centre for Medicine Use and Safety (CMUS), Monash University, working on the development of the new National Clinical Practice Guidelines for Dementia, with a focus on medicine use and safety. She also holds honorary positions as a Research Fellow (Global Health) at the Department of Health Service and Population Research, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, UK, and as a Research Fellow (Health Services) at the Greater Brisbane Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland (UQ). She has a strong interest and expertise in rigorous evidence synthesis methods, advanced statistical analyses, and leveraging large-scale longitudinal datasets to translate evidence into practice and inform national health policies. Her research spans health services, multimorbidity, healthy ageing, cardiovascular and metabolic diseases, surgery, deprescribing, and mental health. Michelle completed her PhD in Medicine at the Central Clinical School, The University of Sydney (USYD), focusing on longitudinal research to improve a multidisciplinary publicly funded bariatric surgery service integrated with a range of adjunct treatments across three hospitals in NSW. Her research program targeted highly complex patients with clinically severe obesity and multiple comorbidities, meaningfully supporting real-world data-driven improvements to publicly funded metabolic and bariatric care pathways. Michelle has successfully obtained nearly 20 competitive awards and research funding exceeding $1 million, including an NHMRC Ideas Grant for a national linkage program. Beyond her collaborations across the UK and Australia, her interdisciplinary network extends to more than 20 countries, including Malaysia. She is passionate about nurturing future researchers and translating evidence to improve real-world health outcomes.

Born in Ethiopia, post primary education at General Wingate Comprehensive Secondary School, Addis Ababa, Ethiopia. There after winning a scholarship to former Czechoslovakia, interred Czech language centre as premedical preparatory school of Charles University and admitted to the former Faculty of Paediatrics, which later named 2nd Medical School of Charles University, where graduated /holding MD in 1992 . Then by interring postgraduate programme he defended, the thesis titled “Non-invasive Methods for Early Diagnosis of some Renal Diseases in Children” and awarded PhD degree in 1996. Then, trained as Paediatrician and later as Clinical Pharmacologist, holds Board Certificate from the Institute for Postgraduate Education in Medicine and is licenced by Czech medical chamber for both Paediatrics and Clinical Pharmacology practice including lectureship. His present position is at Clinical Pharmacology service affiliated to the Department of Medical Chemistry and Clinical Biochemistry, University Hospital in Motol, 2nd Medical School, Charles, University in Prague. The main interest and consultancy area being in particular therapeutic drug monitoring in needy patients including, paediatric and geriatric populations given their pharmacokinetic/pharmacodynamics differences and vulnerability. He is also dedicated to aid dosage adjustment for transplantation patients, oncology patients and others in intensive care including those with renal failure aiming therapy individualization for better overall outcomes and safety. As active in academia participates in pregraduate and postgraduate education both as a faculty member and as invited speaker in the field of clinical pharmacology. Dedicated to safe and better use of medicines for human wellbeing, as a recipient of the grant has successfully included clinical pharmacology education as optional subject in the curriculum for senior medical students at the 2nd Medical Faculty of Charles University teaching every summer term since 2011 to date. Among other scientific activities included bioequivalence studies as co-investigator and principal investigator as well as working on co- grant projects in the past. On long term, he has published more than 100 conference abstracts, including presentations as invited speaker and both oral and poster communications at domestic and international meetings. Tesfaye is also author and co-author of several original articles, case reports, conference proceedings, a monograph, few book-chapters and commentaries as letters to editors in the field of medicine.

Born in Ethiopia, post primary education at General Wingate Comprehensive Secondary School, Addis Ababa, Ethiopia. There after winning a scholarship to former Czechoslovakia, interred Czech language centre as premedical preparatory school of Charles University and admitted to the former Faculty of Paediatrics, which later named 2nd Medical School of Charles University, where graduated /holding MD in 1992 . Then by interring postgraduate programme he defended, the thesis titled “Non-invasive Methods for Early Diagnosis of some Renal Diseases in Children” and awarded PhD degree in 1996. Then, trained as Paediatrician and later as Clinical Pharmacologist, holds Board Certificate from the Institute for Postgraduate Education in Medicine and is licenced by Czech medical chamber for both Paediatrics and Clinical Pharmacology practice including lectureship. His present position is at Clinical Pharmacology service affiliated to the Department of Medical Chemistry and Clinical Biochemistry, University Hospital in Motol, 2nd Medical School, Charles, University in Prague. The main interest and consultancy area being in particular therapeutic drug monitoring in needy patients including, paediatric and geriatric populations given their pharmacokinetic/pharmacodynamics differences and vulnerability. He is also dedicated to aid dosage adjustment for transplantation patients, oncology patients and others in intensive care including those with renal failure aiming therapy individualization for better overall outcomes and safety. As active in academia participates in pregraduate and postgraduate education both as a faculty member and as invited speaker in the field of clinical pharmacology. Dedicated to safe and better use of medicines for human wellbeing, as a recipient of the grant has successfully included clinical pharmacology education as optional subject in the curriculum for senior medical students at the 2nd Medical Faculty of Charles University teaching every summer term since 2011 to date. Among other scientific activities included bioequivalence studies as co-investigator and principal investigator as well as working on co- grant projects in the past. On long term, he has published more than 100 conference abstracts, including presentations as invited speaker and both oral and poster communications at domestic and international meetings. Tesfaye is also author and co-author of several original articles, case reports, conference proceedings, a monograph, few book-chapters and commentaries as letters to editors in the field of medicine.

Subindra Kazi Thapa is a PhD candidate at the Centre for Medicine Use and Safety, Monash University. He holds a Bachelor's in Pharmaceutical Sciences and a Master's in Pharmacy. He has over five years of experience in the pharmaceutical industry, focusing on the formulation of various dosage forms. He is currently pursuing a PhD in pharmacometrics, investigating how ageing and polypharmacy affect frailty progression. His research develops pharmacokinetic and pharmacodynamic models to describe interactions between physiological changes, drug effects, and disease progression in older populations. His work aims to strengthen quantitative modelling to optimize the safe and effective use of medications in vulnerable populations.

Lihui Wang is a Professor and PhD Supervisor at Shenyang Pharmaceutical University, serving as Dean of the Graduate School and Dean of the School of Clinical Pharmacy. His research focuses on tumor pharmacology, cancer epigenetics, drug resistance mechanisms, and molecular targeted therapies. He has led more than 20 national research projects, including two Major New Drug Development Programs and multiple National Natural Science Foundation grants. As corresponding author, he has published over 30 SCI papers in leading journals such as PNAS, Science Advances, EMBO Molecular Medicine, and Cancer Research, and has received national scientific awards. He has also delivered oral presentations at the World Congress of Basic Clinical Pharmacology (WCP), demonstrating strong experience in presenting research at major international scientific conferences.

Dinko Vitezić, born in Rijeka, Croatia, is a prominent clinical pharmacologist with a rich academic and professional background. He holds a Doctor of Medicine degree from the University Rijeka Medical School, a Master of Science degree, and a Doctor of Philosophy degree from the same institution. His career spans various roles, including being a specialist in clinical pharmacology and a course coordinator for undergraduate mandatory courses. Vitezić has contributed significantly to the field through his research, teaching, and publications, with over 100 publications and co-editing a textbook on clinical pharmacology. He has also been involved in drug regulatory and ethical committees, serving as a president and chairman of several organizations. His expertise extends to pharmacoeconomics, medicine policy, and clinical trials, making him a key figure in the field of clinical pharmacology.

Kevin Winardi is a scientific officer in the Laboratory of Ageing and Pharmacology at the Kolling Institute, operating in partnership with the University of Sydney and the Northern Sydney Local Health District. His work integrates systems biology, pharmacology, and biogerontology to understand drug response and its impact to organ function in the context of ageing. He applies proteomics and systems pharmacology approaches to better delineate the molecular complexity of multiple medication usage (polypharmacy), drug-induced harms, and medication cessation (deprescribing). His long-term goal is to advance precision prescribing and improve medication safety practices for older adults through translational ageing research.

A Ph.D. in Molecular Genetics from the University of Groningen, the Netherlands. Recognized as a talent in the Tianjin "131" Innovative Talents Cultivation Project and selected for the Tianjin Higher Education "Young Reserve Talents Support Plan". Awarded the Young Science and Technology Talent Training Special Project by the Ministry of Science and Technology, and serves as a core member of the National Administration of Traditional Chinese Medicine's TCM Inheritance and Innovation Team. Research focuses on the interaction between traditional Chinese medicine and microorganisms, with findings published in leading journals such as Trends in Food Science & Technology, Phytomedicine, Aging Cell, Pharmacological Research, and mSystems. Leads and participates in multiple national and provincial-level research projects, develops TCM-targeted gut microbiota strategies, and holds authorized patents for TCM-bacterial compositions.

Dr. Gestina Aliska, Sp.FK, is a lecturer in the Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, and a Clinical Pharmacologist at Dr. M. Djamil General Hospital, Padang, West Sumatra, Indonesia. She obtained her medical degree from Universitas Andalas and completed her Clinical Pharmacology specialist training and doctoral degree in Medical Sciences at Universitas Indonesia. Her research focuses on clinical pharmacology, with particular interests in sepsis, COVID-19, antimicrobial resistance, and pharmacogenomics. Her work emphasizes pharmacokinetic/pharmacodynamic optimization, therapeutic drug monitoring, biomarker-based therapy, and individualized treatment strategies in critically ill patients. Dr. Aliska is actively involved in funded clinical research, international scientific publications, and undergraduate and postgraduate medical education. She teaches clinical and molecular pharmacology and contributes to the development of evidence-based pharmacotherapeutic practices, with a strong commitment to advancing rational and personalized medicine in Indonesia.

Teoni Antonopoulos is an intern pharmacist and Bachelor of Pharmacy (Honours) graduate from the University of Sydney. Her honours research focusses on the potential for implementation of pharmacogenomic-guided antiplatelet therapy within Australia, to improve patient outcomes.

Dr Shubham Atal is an Additional Professor of Pharmacology at the All India Institute of Medical Sciences (AIIMS), Bhopal, India. He is a clinician-scientist with academic and research interests in clinical pharmacology, precision medicine in psychiatry and oncology, rational use of medicines, drug interactions and management of NCD’s. Having completed his MBBS, MD (Pharmacology) from India and MSc (Clinical Research) from Ireland, he is currently pursuing his PhD focusing on pharmacogenetics of antidepressant treatment response. He has completed brief stints as visiting faculty at the Harvard Medical School, Boston and a fellowship in personalised healthcare from Erasmus Medical Center, Rotterdam. Dr Atal has authored multiple peer-reviewed publications and is actively involved in undergraduate and postgraduate medical education, clinical research methodology, and institutional drug policy initiatives. His ongoing work aims to translate pharmacogenetic insights into personalized and evidence-based care.

A graduate student under the supervision of Dr Richard B Kim at Western University in London, Ontario, Canada. My research interests are in pharmacogenetic and pharmacogenomic predictors of toxicities to cancer chemotherapeutics.

Collet Dandara is a Professor of Human Genetics and Principal Investigator of the Pharmacogenomics and Drug Metabolism Research Group at the University of Cape Town. From the start of his career, his research focused on pharmacogenetics and later pharmacogenomics, characterising African genomes to identify genomic factors influencing differential drug responses. His work has established a foundation for understanding genetic variants of pharmacogenomic importance in African populations, leading to novel discoveries and mechanistic insights into these variants and their networks. The group’s research has also explored the pharmacogenomics of widely used herbal medicines. Professor Dandara was nominated Vice-Chair of the African Consortium of Pharmacogenomics (APC) in 2018, is a member of the African Society of Human Genetics (AfSHG), serves on the International Scientific Advisory Committee for the Human Variome Project (HVP), and is involved in the Global Genomic Medicine Collaboration (G2MC) and the Global Pharmacogenomics Network. He has authored over 140 publications, with an H-index of 26 and i10-index of 60, and serves on several editorial boards. He received the TWAS Young Affiliate Award in 2012 and sits on the TWAS Young Affiliate Network Executive. A finalist in the 2014 NSTF Awards for Human Capacity Development, he has supervised numerous MSc and PhD students and serves on multiple University of Cape Town committees, including the Faculty of Health Sciences Transformation Committee, and on the SAYAS selection committee.

Dr. Reka Devanathan, MD & DNB Pharmacology & Toxicology, is a pharmacologist with over four years of experience in academia and research, and has recently served as a Senior Resident in the Department of Pharmacology at JIPMER, Puducherry. Her primary interest is in pharmacogenomics, where she has analysed genetic variants (e.g., NUDT15, ITPA, MOCOS, and TPMT) to provide personalized medication recommendations, optimizing therapeutic efficacy and minimizing adverse drug reactions (ADRs). She has collaborated with multidisciplinary healthcare teams, including clinicians, to integrate pharmacogenetic (PGx) testing into standard clinical workflows, facilitating precision medicine at the point of care. In addition, she has leveraged bioinformatics tools and genomic databases, such as PharmGKB and CPIC, to interpret complex genotype-phenotype associations.

Kathleen Glavin is a graduate student working under the supervision of Dr. Richard B. Kim at Western University, London, Ontario, Canada. Her research interests focus on pharmacogenetics and phenotypic predictors of drug metabolism.

Dr. Shubhkarman Jit Singh Dhillon is a Junior Resident in the Department of Pharmacology at Government Medical College and Hospital, Chandigarh, India. He completed his MBBS from the same college and is currently pursuing MD Pharmacology. His research interests include Pharmacovigilance and Pharmacogenomics. He is a student researcher and holds memberships of BPS and ASPET.

Presenting author is a medical student in School of Medicine and Health Sciences in the Catholic University of Atma Jaya Indonesia.

Dr Julia Netylko completed her medical degree at Moscow State University, followed by residency in cardiology. She joined the Cancer Therapies group at the Murdoch Children’s Research Institute in October 2024. Her research focuses on pharmacogenomics in paediatric oncology, with current projects investigating genetic predisposition to anthracycline-induced cardiotoxicity and genotype-informed dosing of tacrolimus in solid organ transplant recipients. Julia is passionate about advancing personalised medicine approaches to improve treatment safety and outcomes for children.

Dr. Ratinder Jhaj is currently working a Professor in the Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhopal, India. She completed her M.D. Pharmacology and D.M. Clinical Pharmacology from Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. Her research interest lies in pharmacovigilance, prescription research, pharmacogenetics, antimicrobial stewardship and bioethics. She is the coordinator of the Regional Training Centre in Pharmacovigilance for Madhya Pradesh and Chhattisgarh under the Pharmacovigilance Programme of India and a member of the National Core Training Panel for Pharmacovigilance and the State AEFI Causality Committee. She is also a member of the Institutional Human and Animal Ethics Committees, AIIMS Bhopal. Additionally, Dr. Ratinder Jhaj is affiliated with many scientific organisations viz. Indian Pharmacological Society (IPS), Forum for Ethics Review Committees of India (FERCI), Society of Pharmacovigilance, India (SOPI), Society of Pharmacovigilance (ISOP), South Asian Chapter of American College of Clinical Pharmacology (SAC ACCP), and is one of the founding members of the Society of Antimicrobial Stewardship Practices in India (SASPI).

Dr Rahini Ragavan is a Lecturer (Teaching Focussed) in the Department of Physiology and Pharmacology, La Trobe University. Her PhD was in the Department of Pharmacology, Monash University and her focus was on investigating the cardiovascular effects of animal venom. She has over 8 years of experience delivering workshops, tutorials and wet practicals to undergraduate science, allied health and biomedical science students. Recently she has been involved in curriculum development for third year pharmacology subjects. Her passion is inspiring the next generation of STEM students to continue their education in research and STEM related careers. She is also interested in collaborating with other academics in education research, more specifically how to retain long term student engagement and involvement in STEM courses.

Dr. Varsha Rathore completed her Ph.D. in 2025 at the College of Medicine, National Taiwan University. Her doctoral training was supported by the Taiwan International Graduate Program and fellowships from the National Science and Technology Council (NSTC), Taiwan, and involved interdisciplinary collaborations with Academia Sinica and National Tsing Hua University. Her research interests focus on cancer biology and pharmacology, particularly understanding how cancer cells adapt to stress and therapeutic challenges. Beyond research, Dr. Rathore enjoys practicing yoga and exploring new cultures through travel, which she finds inspiring for both personal growth and scientific creativity.

Hans Agabe Mangatur Sagala was born in Jakarta, Indonesia, and is currently an undergraduate medical student at the Faculty of Medicine, Universitas Sumatera Utara. He has a strong academic interest in clinical research and medical education, and recently delivered a podium presentation on a metaanalysis study at the 48th Annual Scientific Meeting of the Indonesian Urological Association (ASMIUA). He served as the Human Resource Development Coordinator of SCOME CIMSA Indonesia (2024-2025) and has been actively involved as a IFMSA Medical Education Trainer, delivering several training sessions for medical students. Alongside these roles, he frequently participates in Christian faith-based events, community service initiatives, and student leadership development activities on campus. Beyond medicine, Hans has a deep passion for the arts, particularly choral music. Back in 2018, he was part of The Resonanz Childrens’ Choir that won the 30th European Grand Prix for Choral Singing in Maribor, Slovenia, as well as other international choral competitions in Europe.

Dr. Fadi G. Saqallah is an Assistant Professor at the Faculty of Pharmacy, Al-Zaytoonah University of Jordan, where he teaches Medicinal Chemistry, Drug Design, and Phytochemistry. He also serves as the Head of the Advisory Board for the Pharmacy Students’ Research Club (PSRC), actively supervising undergraduate research projects and guiding students in scientific writing, conferences, and competitions to strengthen their research and analytical skills. Dr. Saqallah earned his Ph.D. in Pharmaceutical Chemistry from Universiti Sains Malaysia, where his research focused on the design and synthesis of novel dengue virus protease inhibitors, integrating computational drug discovery with organic synthesis and in vitro assays. In addition to his academic career, he has professional experience as a Senior Pharmacist, contributing to patient care, pharmacy management, and clinical supervision. His research interests span antiplatelet, anti-atherosclerotic, and anti-hyperlipidemic agents, as well as antineoplastic and antiviral drug discovery.

Dr. Kiruthika Sivagourounadin is an Assistant Professor of Pharmacology at JIPMER, an undergraduate teaching hospital located in Karaikal, South India. She has nearly 8.5 years of teaching and research experience and, as an early-career faculty member, has guided undergraduate students in undertaking short-term research projects. Dr. Sivagourounadin has conducted small research studies in pharmacovigilance and medical education, contributing to the advancement of safe medication use and educational practices. Her academic and research interests include pharmacogenomics, clinical trials, and biostatistics. Through her teaching, mentorship, and research activities, she is committed to fostering a rigorous scientific approach among students while exploring translational applications of pharmacological research. Her work reflects a dedication to both education and evidence-based medicine, emphasizing the integration of research and practical clinical insights in the pharmacological field.

Puiu Olivian STOVICEK is a Habilitated Associate Professor at the Faculty of Nursing, Titu Maiorescu University of Bucharest, Romania, and an Adjunct Associate Professor at the Faculty of Psychology, University of Craiova. He is a senior physician in clinical pharmacology at the “Sf. Nectarie” Oncology Center in Craiova, where he serves as a subinvestigator in international phase I, II, and III clinical trials. He also holds certifications in palliative care and healthcare management. His main professional interests focus on integrating clinical pharmacology and psycho-oncology into a holistic approach to oncology and palliative care. An important line of his research examines the impact of oncological treatments on mental status, associated psychological symptoms, and quality of life. His academic work includes a significant number of books, book chapters, and research articles published nationally and internationally.

Puiu Olivian STOVICEK is a Habilitated Associate Professor at the Faculty of Nursing, Titu Maiorescu University of Bucharest, Romania, and an Adjunct Associate Professor at the Faculty of Psychology, University of Craiova. He is a senior physician in clinical pharmacology at the “Sf. Nectarie” Oncology Center in Craiova, where he serves as a subinvestigator in international phase I, II, and III clinical trials. He also holds certifications in palliative care and healthcare management. His main professional interests focus on integrating clinical pharmacology and psycho-oncology into a holistic approach to oncology and palliative care. An important line of his research examines the impact of oncological treatments on mental status, associated psychological symptoms, and quality of life. His academic work includes a significant number of books, book chapters, and research articles published nationally and internationally.

Puiu Olivian STOVICEK is a Habilitated Associate Professor at the Faculty of Nursing, Titu Maiorescu University of Bucharest, Romania, and an Adjunct Associate Professor at the Faculty of Psychology, University of Craiova. He is a senior physician in clinical pharmacology at the “Sf. Nectarie” Oncology Center in Craiova, where he serves as a subinvestigator in international phase I, II, and III clinical trials. He also holds certifications in palliative care and healthcare management. His main professional interests focus on integrating clinical pharmacology and psycho-oncology into a holistic approach to oncology and palliative care. An important line of his research examines the impact of oncological treatments on mental status, associated psychological symptoms, and quality of life. His academic work includes a significant number of books, book chapters, and research articles published nationally and internationally.

Milan is a Post-Doctoral Research Fellow in the Department of Medicine at the University of Otago, Christchurch. His research focuses on leveraging routinely collected healthcare data to enhance electronic clinical decision support (CDS) for hospital medication prescribing. He has a particular interest in CDS alerts, their impact on prescribing behavior and clinical outcomes, and strategies to reduce alert fatigue. He also has a keen interest in prescribing education.

Dr Showmika Supti completed her Bachelor of Pharmacy (Honours) at Monash University Parkville in 2018, earning the Sir John Monash Medal for academic excellence and commitment to social justice during her undergraduate studies. Showmika began her career as an intern pharmacist in community practice before becoming a registered community pharmacist and later transitioning into a hospital pharmacist role, where she developed clinical and multidisciplinary experience. She went on to complete a PhD in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics at Monash University in 2024, where her research focused on how Alzheimer’s disease-related factors affect blood-brain barrier transport and astrocyte release of apolipoprotein E isoforms. During her PhD, she received recognition for her research, including best poster awards at international conferences, and was selected as the Faculty ambassador for the Globalisation of Pharmaceutics Education Network (GPEN) conference 2024 at the University of Copenhagen, Denmark. Throughout her doctoral studies, Showmika gained extensive experience teaching a wide range of undergraduate and postgraduate units in both pharmacy and pharmaceutical sciences, with substantial involvement in multiple units and OSCEs; a reflection of her broad expertise in curriculum delivery and assessment. In addition to her academic roles, she is an experienced Clinical Pharmacist, developing broad expertise in clinical trials and hospital pharmacy settings, while collaborating with multidisciplinary teams to deliver patient-centred care. Showmika is passionate about mentoring students and fostering an inclusive learning environment, always keen to implement innovative technologies and approaches to advance student engagement.

Ivana Šutej is an Associate Professor at the School of Dental Medicine, chair of pharmacology department at University of Zagreb. Her work focuses on dental pharmacotherapy and medication utilization, with particular emphasis on rational antibiotic prescribing in dentistry and the development of evidence-based teaching materials to strengthen students’ understanding of appropriate medication use.

Dr Arlene Taylor is an independent consultant with interests in precision medicine, pharmacogenomics, and evidence-based solutions that improve health (and other) outcomes for all members of society. With a background in clinical medicine, and extensive experience in associated fields, Dr Taylor has committed herself to applying her skills to create meaningful change.

Associate Professor Tie Lu, Deputy Head of the Department of Pharmacology at Peking University, is an independent Principal Investigator (PI) and focusing on molecular pharmacology. Dr. Tie has been recognized by the Beijing Youth Talent Program and leads several educational reform projects sponsored by the Ministry of Education and the Chinese Medical Association, and has published educational research as corresponding author in journals including Medical Education. Her teaching innovations have earned her multiple accolades: First Prize and the Digital Education Special Award at the 7th National Higher Education Blended Teaching Design Innovation Competition, and Third Prize at the 5th Beijing Higher Education Teacher Teaching Innovation Competition. She has authored or co-authored 21 textbooks and has been repeatedly honored as an Outstanding Teacher at Peking University. Her research, published as corresponding (including co-corresponding) author in high-impact journals such as Cell, Blood, and Nature Communications, has accumulated over 1,600 citations.

Professor of the MEXT program for clinical research University of the Ryukyu Hospital and Emeritus Professor of Clinical Pharmacology & Therapeutics, University of the Ryukyus School of Medicine

Katerina Venderova, PharmD, PhD, is an Associate Professor of Biomedical Sciences at the Kaiser Permanente School of Medicine in Pasadena, CA. She combines her expertise in pharmacology with innovative curriculum design to create active learning experiences that bridge basic science and clinical application and champions the integration of foundational sciences into clinical education through competency-based medical education (CBME) frameworks. Committed to educational scholarship and collaboration, she led initiatives to align assessment and instruction with CBME principles and works across disciplines and organizations to advance integrated, learner-centered approaches that prepare future health professionals for practice.

Megan is an education-focused lecturer in the faculty of Pharmacy and Pharmaceutical Sciences and a practising pharmacist. Megan has a particular interest in integrative curriculum development to enhance student learning experiences. With a background in microbiology and molecular biology, Megan continues to explore innovative ways to connect conceptual understanding of these fields with discipline-specific and generic skills, as well as seeking to incorporate diverse perspectives such as those of First Nations peoples.

Micha Wilhelmus is associate professor at the department of Anatomy and Neurosciences of the Amsterdam UMC, Amsterdam, The Netherlands. He is both registered as Clinical Pharmacologist and European registered pharmacologist. His research focusses on finding druggable drug targets to counteract neurodegeneration in neurodegenerative diseases. He is programme director of the bachelor Biomedical Sciences of the VU, chair of the programme committee of the Neuroscience master, and course coordinator of 4 pharmacology focused courses at both bachelor and master level in various programmes of the VU University. In addition, he is chair of the education committee of the Dutch Pharmacological Society and part of the daily management of the national cohort of Biomedical Sciences programmes in The Netherlands.

Faqih Alkhairi Winata is a medical student at the Faculty of Medicine, Universitas Sumatera Utara. He is actively engaged in academic and organizational activities and currently serves as an Anatomy Laboratory Assistant at the Faculty of Medicine, Universitas Sumatera Utara. He has organizational experience as the General Secretary of FOSKAMI at the Student Executive Board of the Faculty of Medicine, Universitas Sumatera Utara. He is a Turbo Talk Presenter at ICTROMI, highlighting his strong interest in medical communication and public speaking. He also serves as an Indonesian Inspiration Ambassador representing North Sumatra (Batch 15), reflecting his leadership and commitment to youth empowerment.

Dr. Hu graduated from China Pharmaceutical University in 2012. After graduation, she joined the Department of Pharmacy in a hospital, engaging in clinical pharmacy work. Her research directions are Therapeutic Drug Monitoring (TDM) and personalized medicine. She has published over 30 SCI papers and has been granted funding for more than 10 research projects.

Background: Anticoagulant rodenticides induce coagulation factor deficiency. Therapeutic plasma exchange (TPE) directly removes circulating toxins and replenishes coagulation factors.Objective: To evaluate the efficacy and safety of TPE in treating acute anticoagulant rodenticide poisoning.Methods: A cross-sectional study included 20 patients (PE group: n=7 , HP group: n=13). Toxin clearance, INR recovery, and length of stay (LOS) were compared.Results: PE group showed higher median clearance rates (subsequent sessions: 44.7% vs. initial 15.4%) and shorter median INR recovery time (2 vs. 4 days) and LOS (11 vs. 16 days) than HP group (all P<0.05). Two cases of VK1 allergy were noted.Conclusion: Compared with HP, TPE achieves higher toxin clearance, accelerates coagulation recovery, and has a favorable safety profile.

Estefanía Siller Flores is a fourth-year medical student at the School of Medicine and Health Sciences, Tec de Monterrey. She has a strong interest in clinical research, particularly in the epidemiological study of chronic non-communicable diseases and their impact on vulnerable populations. She has focused on identifying socioeconomic barriers to hypertension and obesity treatment. Her goal is to contribute to the development of more equitable healthcare strategies and improve clinical guideline adherence in Mexico.

Dr. Hemanth Kumar Boyina is a Professor of Pharmacology at Chandigarh University, Punjab, India, with over 15 +years of experience in teaching and research. His expertise lies in neuropharmacology and translational neuroscience, focusing on neurodegenerative and neurological disorders such as Alzheimer’s disease, Parkinson’s disease, vascular dementia, and depression models. He has international research experience as a SERB-SIRE Visiting Fellow at the University of California, San Diego, USA, where he investigated molecular mechanisms of neuroprotection in Alzheimer’s disease. His research integrates behavioral neuroscience, molecular biology, and nanomedicine-based drug delivery. Dr. Boyina has published over 20 + research and review articles and actively mentors undergraduate, postgraduate, and doctoral students. His current interests include natural product-based therapeutics and computational pharmacology for CNS and metabolic disorders.

Concluded Masters Degree in Medicine in the Faculty of Medicine of the University of Porto, Portugal, in 2018. Working as a Clinical Pharmacology trainee in S. João University Hospital, Porto, Portugal, since 2024. Teaching assistant in Basic Pharmacology and Clinical Pharmacology and Therapeutics in the Faculty of Medicine of the University of Porto, since 2020. PhD candidate (Pharmacology and Toxicology) in the Faculty of Medicine of the University of Porto, since 2019.

Mojca Kržan, MD, PHD Curriculum vitae EDUCATION: Graduated in 1886 at Faculty of Medicine, University of Ljubljana. In 1990 defended M.Sc. thesis and in 1995 Ph.D. thesis in pharmacology of cardiac histamine receptors. From September 1996 till 1998 I spent as a postdoctoral fellow at NINDS - NIH in Bethesda, Maryland, USA. RESEARCH INTERESTS: basic pharmacology and neuropharmacology. EMPLOYMENT: from 1986 till 1994 I was a research fellow; later teaching assistant, from 2003 till present a professor of pharmacology at the Department of Pharmacology, Faculty of Medicine, University of Ljubljana. I served two terms as Head of Department. MEMBERSHIPS: I am member of Slovenian Pharmacological Society and Federation of European Pharmacological Societies, where I served as president from 2018-22.

Dave Lewis is Professor of Education for Professional & Sustainable Development at the University of Leeds, UK. His activities focus on supporting the professional development of learners. He led the development of capstone projects as alternatives to traditional undergraduate final year/Honours projects across the UK Biosciences, and internationally. He used his research experience involving animals to create learning opportunities for undergraduates, leading the development of the British Pharmacological Societies research animal sciences curriculum. Chair of IUPHARs Integrative & Organ Systems Initiative he collaborates with national/regional pharmacological societies and other stakeholders to co-create professional development opportunities, tailored to the needs of host country, for all those involved in the care and use of animals for research. His current activities are supporting colleagues in undertaking humane high-quality research involving animals, and on their journey to transition to New Approach Methodologies/Non-Animal Technologies. He is currently the British Pharmacological Society's Vice-President (Academic Development)

I have over 20 years of experience teaching pharmacology. My teaching philosophy emphasises developing critical thinking and lifelong learning skills, enabling students to adapt to evolving scientific knowledge and clinical practice. I am a passionate and innovative educator and a leader in the development and implementation of educational advances within the School of Biomedical Sciences (SBMS), UNSW, a as recognised by a UNSW Vice-Chancellor’s Award for Teaching Excellence (2017) and the Faculty of Medicine & Health Educator of the Year Award (2022). I am currently Director of Teaching, SBMS (2021–present). Previously, I served as Head of Teaching, Department of Pharmacology (2016–2021), Chair of the ASCEPT Education Forum (2021–2022), Chair of the ASCEPT Scientific Advisory Committee (2015–2016), and ASCEPT Board Member (2015–2016; 2021–2022).

Dr. Hemanth Kumar Boyina is a Professor of Pharmacology at Chandigarh University, Punjab, India, with over 15 +years of experience in teaching and research. His expertise lies in neuropharmacology and translational neuroscience, focusing on neurodegenerative and neurological disorders such as Alzheimer’s disease, Parkinson’s disease, vascular dementia, and depression models. He has international research experience as a SERB-SIRE Visiting Fellow at the University of California, San Diego, USA, where he investigated molecular mechanisms of neuroprotection in Alzheimer’s disease. His research integrates behavioral neuroscience, molecular biology, and nanomedicine-based drug delivery. Dr. Boyina has published over 20 + research and review articles and actively mentors undergraduate, postgraduate, and doctoral students. His current interests include Digital Health, Natural product-based therapeutics, and computational pharmacology for CNS and metabolic disorders.